Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Anchalee AvihingsanonMichael D HughesRobert SalataCatherine GodfreyCaitlyn McCarthyPeter MugyenyiEvelyn HoggRobert GrossSandra W CardosoAggrey BukuruMumbi MakangaSharlaa Badal-AesenVidya MaveBeatrice Wangari NdegeSandy Nerette FontainWadzanai SamanekaRode SecoursMarije Van SchalkwykRosie MngqibisaLerato MohapiJavier ValenciaPatcharaphan SugandhavesaEsmelda MontalbanCornelius MunyangaMaganizo B ChagomeranaBreno R SantosNagalingeswaran KumarasamyCecilia KanyamaRobert T SchooleyJohn W MellorsCarole L WallisAnn C CollierBeatriz Grinsztejnnull nullPublished in: Journal of the International AIDS Society (2022)
Third-line regimens comprising of RAL, DRV/r and/or ETR were very well tolerated and had high rates of durable virologic suppression among PLWH in LMICs who were failing on second-line PI-based ART prior to the availability of dolutegravir.